Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-10T15:42:55.748Z Has data issue: false hasContentIssue false
  • English
  • Français

Combined use of platelet serotonergic markers and psychopathological scales as diagnostic screening of a psychotic versus a depressive disorder

Published online by Cambridge University Press:  16 April 2020

Nicolas Ramirez ,
Belén Arranz ,
Carmen Martín  and
Luis San
Nicolas Ramirez*
Affiliation:
Benito Menni, CASM, Hospital de Granollers, Mental Health Care Institute, Avda. Francesc Ribas s/n, 08400 Granollers, Barcelona, Spain
Belén Arranz
Affiliation:
Benito Menni, CASM, Hospital de Granollers, Mental Health Care Institute, Avda. Francesc Ribas s/n, 08400 Granollers, Barcelona, Spain
Carmen Martín
Affiliation:
Benito Menni, CASM, Hospital de Granollers, Mental Health Care Institute, Avda. Francesc Ribas s/n, 08400 Granollers, Barcelona, Spain
Luis San
Affiliation:
Benito Menni, CASM, Hospital de Granollers, Mental Health Care Institute, Avda. Francesc Ribas s/n, 08400 Granollers, Barcelona, Spain
*
*Corresponding author. E-mail address: 32698nrn@comb.es (N. Ramirez).
Get access

Abstract

A single case of a patient suffering from a first psychotic episode and the differential diagnoses between affective and psychosis is performed throughout the combined use of peripheral serotonergic markers and clinical psychopathological scales during a 6-months follow-up. The results suggest the need of performing further studies combining biological and clinical markers of psychiatric disorders.

Keywords

Serotonergic functionPsychosisDepressionPsychopathological scales
Type
Short communication
Information
European Psychiatry , Volume 18 , Issue 7 , November 2003 , pp. 369 - 371
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arranz, BRosel, PSarró, SRamírez, NDueñas, RCano, R, et al. Altered platelet serotonin 5-HT2A receptor density and second messenger inositol trisphosphate levels in drug-free schizophrenic patients. Psychiatry Res 2003;118(2):165–74.CrossRefGoogle ScholarPubMed
Copolov, DCrook, J. Biological markers and schizophrenia. Aust New Zealand J Psychiatry 2000;34 (Suppl):108–12.CrossRefGoogle Scholar
Rosel, PArranz, BSan, LUrretavizcaya, MMarcusson, JNavarro, MA. 5-HT2A receptors and their second messenger IP3 are only correlated in human brain and not in platelets. Neurosci Res Commun 1999;25(3):129–38.3.0.CO;2-#>CrossRefGoogle Scholar
Rosel, PArranz, BVallejo, JAlvarez, PMenchon, JMPalencia, T, et al. Altered [3H]imipramine and 5-HT2 but not [3H]paroxetine binding sites in platelets from depressed patients. J Affect Disord 1999;52:225–33.CrossRefGoogle Scholar
Vallejo, JRosel, PArranz, BUrretavizcaya, MMenchón, JMContreras, F, et al. Loss of circadian variation of platelet [3H]imipramine binding in delusional compared with non-delusional endogenously depressed patients. J Affect Disord 2002;72(1):95–102.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.